

## Ikonisys completed a capital increase through a private placement

Paris, July 18, 2024 – 6:30 pm CEST - Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “Issuer”), today announces that it has completed a capital increase of €250k, by way of a private placement with the investment company CC Holding Srl, in order to strengthen its financial resources and pursue its commercial development.

CC Holding Srl is Claudio Costamagna's personal holding company. Claudio Costamagna is an Italian banker, former Chairman of the Italian National Promotional Institution, Cassa Depositi e Prestiti, and of Advanced Accelerator Applications prior to its sale to Novartis.

The net proceeds of this issue, amounting to €250k, should provide the Issuer with additional resources to support its commercial development, by financing its working capital needs and extending its financial visibility, while expanding its shareholder base with a knowledgeable investor.

**Mario Crovetto, CEO of Ikonisys**, states: *“We are thrilled to welcome CC Holding Srl into Ikonisys’ capital. As a renowned and expert investor, their involvement testifies to their trust in our advanced technology and long-term innovation capacity. These new proceeds will provide us with financial resources required to further support our short-term commercial development. Moving forward, we look ahead to seizing growth opportunities to expand our commercial footprint in the US and Europe and fully leverage the recent acquisition of Hospitex.”*

### Legal terms of the Capital Increase

The implementation of this capital increase, carried out with cancellation of shareholders' subscription rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting held on July 17, 2024 (the “**Capital Increase**”).

The new shares will be issued on the basis of the 9<sup>th</sup> resolution of the Issuer's shareholders' meeting held on June 28, 2023. The settlement-delivery of the new shares will take place on July 22, 2024.

The Capital Increase did not require the approval of a notice (“**prospectus**”) by the *Autorité des marchés financiers* (the “**AMF**”).

### Main terms of the Capital Increase

The Issuer has issued a total of 166,666 new ordinary shares, with a par value of €0.5 each, to the investor, pursuant to article L. 411-2 1° of the French Monetary and Financial Code, in accordance with the 9<sup>th</sup> resolution passed by its Annual General Meeting on June 28, 2023.

The issuance price of the new shares issued under the Capital Increase, equal to €1.5 per share, represents a premium of approximately 2% on the Ikonisys share price at the close of July 17, 2024.

## Impact of the transaction in terms of liquidity risk management and financing horizon

As at December 31, 2023, and as mentioned in the financial report published on July 8, 2024, the Issuer's consolidated cash position amounted to €9.4k.

In order to strengthen its financial resources, Ikonisys completed a capital increase of €1m on December 28, 2023 and more recently a capital increase of €150k on June 3, 2024.

Taking into account these elements, the Capital Increase completed and the previously secured financing facility, the Company considers that it is now in a position to meet its financing needs for more than 12 months.

## Impact of the Capital Increase on a shareholder holding 1% of the capital

On the basis of the 10,551,424 shares outstanding, the impact on the shareholding of a shareholder holding 1% of the Issuer's capital prior to the transaction is as follows:

	On a non-diluted basis	On a diluted basis <sup>1</sup>
Before completion of the Capital Increase	1.00%	0.96 %
After issuance of the 166,666 shares resulting from the Capital Increase	0.98 %	0.95 %

<sup>1</sup> Dilution takes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum indicative number of 397,043 new shares.

## Capital breakdown before and after completion of the Capital Increase

Before the Capital Increase:

Shareholder	Number of shares	% of share capital and voting rights
Cambria Co-Investment Fund	5,268,989	49.94%
Cambria Equity Partners	2,174,049	20.60%
MC Consulting*	351,464	3.33%
Free float	2,756,922	26.13%
<b>Total</b>	<b>10,551,424</b>	<b>100.00%</b>

\*Holding company of the CEO, Mario Crovetto

After the Capital Increase:

Shareholder	Number of shares	% of share capital and voting rights
Cambria Co-Investment Fund	5,268,989	49.16%
Cambria Equity Partners	2,174,049	20.28%
MC Consulting*	351,464	3.28%
Free float	2,923,588	27.28%
<b>Total</b>	<b>10,718,090</b>	<b>100.00%</b>

\*Holding company of the CEO, Mario Crovetto

## Risk factors related to the Issuer

Detailed information about the Issuer, including its business, financial information, results, outlook and related risk factors, is contained in the 2023 annual financial report for the financial year ended December 31, 2023, published on July 8, 2024. This document, together with other regulated information and all the Issuer's press releases, is available on the Issuer's website ([www.ikonisys-finance.com](http://www.ikonisys-finance.com)).

## About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to [www.ikonisys.com](http://www.ikonisys.com)

## Contacts

---

<b>Ikonisys</b>	<b>NewCap</b>	<b>NewCap</b>
Alessandro Mauri	Louis-Victor Delouvrier/Aurélie Manavarere	Nicolas Merigeau
CFO	Investor Relations	Media Relations
<a href="mailto:investors@ikonisys.com">investors@ikonisys.com</a>	<a href="mailto:ikonisys@newcap.eu">ikonisys@newcap.eu</a>	<a href="mailto:ikonisys@newcap.eu">ikonisys@newcap.eu</a>
	Tel.: +33 (0)1 44 71 94 94	Tel.: +33 (0)1 44 71 94 98

## Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.